Early Response Data for Pediatric Patients with Non-Hodgkin Lymphoma Treated with CD19 Chimeric Antigen Receptor (CAR) T-Cells
Julie Rivers(Seattle Children's Hospital), Rebecca Gardner(Seattle Children's Hospital), Julie R. Park(Seattle Children's Hospital), Corinne Summers(Seattle Children's Hospital), Alan S. Wayne(University of Southern California), Olivia Finney(Seattle Children's Hospital), Michael A. Pulsipher(Primary Children's Hospital), Colleen Annesley(Unknown), Michael C. Jensen(Seattle Children's Hospital)
Cited by 19
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k